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Background: Feasibility studies and external pilot studies are used increasingly to inform planning decisions related
to a definitive randomized controlled trial. These studies can provide information on process measures, such as
consent rates, treatment fidelity and compliance, and methods of outcome measurement. Additionally, they can
provide initial parameter estimates for a sample size calculation, such as a standard deviation or the ‘success’ rate
for a binary outcome in the control group. However, the issue of estimating treatment effects in pilot or feasibility
studies is controversial.
Methodological discussion: Between-group estimates of treatment effect from pilot studies are sometimes used
to calculate the sample size for a main trial, alongside estimated standard deviations. However, whilst estimating a
standard deviation is an empirical matter, a targeted treatment effect should be established in terms of clinical
judgement, as a minimum important difference (MID), not through analysis of pilot data. Secondly, between-group
effects measured in pilot studies are sometimes used to indicate the magnitude of an effect that might be
obtained in a main trial, and a decision on progression made with reference to the associated confidence interval.
Such estimates will be imprecise in typically small pilot studies and therefore do not allow a robust decision on a
main trial; both a decision to proceed and a decision not to proceed may be made too readily. Thirdly, a within-
group change might be estimated from a pilot or a feasibility study in a desire to assess the potential efficacy of a
novel intervention prior to testing it in a main trial, but again such estimates are liable to be imprecise and do not
allow sound causal inferences.
Conclusion: Treatment effects calculated from pilot or feasibility studies should not be the basis of a sample size
calculation for a main trial, as the MID to be detected should be based primarily on clinical judgement rather than
statistics. Deciding on progression to a main trial based on these treatment effects is also misguided, as they will
normally be imprecise, and may be biased if the pilot or feasibility study is unrepresentative of the main trial.
Keywords: Pilot studies, Feasibility studies, Treatment effects, Randomized controlled trialsBackground
Feasibility studies and external pilot studies are increasingly
common precursors to a main, or definitive, randomized
controlled trial [1, 2]. These studies may address process
measures, such as the number of eligible patients in a centre,
the consent rate, rates of treatment fidelity and compliance,
and the methods of randomization, blinding and outcome
measurement [3, 4]. They may also function to estimate pa-
rameters required for a sample size calculation, such as the
standard deviation of a continuous outcome measure [5, 6],
or possibly the control group proportion for a binary© The Author(s). 2019 Open Access This artic
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could be estimated in the case of a cluster trial, though this
is subject to important caveats regarding sample size [7].
A pilot study is considered to be a version of the main
trial (or possibly part thereof) run on a smaller scale in
order to determine whether its components work effect-
ively together, and thus normally involves randomization
(or at least allocation) to two or more groups, whereas a
feasibility study may be a single-group study and need
not adopt the design of the intended main trial [8, 9].
Both pilot and feasibility studies can in principle be used to
estimate a treatment effect, though the CONSORT exten-
sion for such studies does not recommend formal hypoth-
esis testing of such effects [10]. In a pilot study, both ale is distributed under the terms of the Creative Commons Attribution 4.0
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in a single-group feasibility study, only a within-group esti-
mate is possible. The motivation for such estimates may be
to determine an effect that may be either important and/or
realistic for a main trial [11]. Deriving these measures of ef-
fect may seem attractive, in an attempt to maximize the in-
formation generated by the pilot or feasibility study. In
practice, however, producing such estimates is less straight-
forward and may be misguided.
Common misuses of between-group estimates of
treatment effect
Estimating the minimum important difference for a sample
size calculation
Reviews suggest that researchers sometimes use a between-
group estimate of effect (or a standardized effect size) from
a pilot or feasibility study as the basis of a sample size calcu-
lation for a main trial [12–15]. For example, Uszynski et al.
[16] and Kemp et al. [17] used observed between-group dif-
ferences (expressed as standardized effect sizes) and Mollart
et al. [18] used observed between-group differences in pro-
portions to determine the sample size required for a subse-
quent main trial. If this strategy is adopted in order to
determine an important effect on which the sample size
calculation should be based, it seems ill-founded. An effect
such as a mean difference estimated from a pilot study may
give some indication of the effect that may be found. How-
ever, it does not indicate the effect that is worth finding,
which needs to be informed by clinical judgement and pa-
tient perspectives, and expressed as an a priori minimum
important difference (MID)—one sufficiently large to affect
clinical decision-making [3, 19]. Moreover, basing the sam-
ple size for a continuous outcome measure on a standard-
ized effect size is uninformative, as it confounds the mean
difference with its standard deviation, focusing attention
away from the absolute magnitude of the difference. It also
further obscures the important distinction that, for sample
size purposes, the standard deviation needs to be calculated
but the magnitude of the difference needs to be specified. A
further problem is that any such effect from a pilot study of
typical size will often be too imprecise to provide useful
guidance for a sample size calculation [19, 20].
Using the MID to decide whether to proceed to main trial
Another possible purpose of estimating a between-group
treatment effect is to gain an indication as to whether an
MID, determined a priori, might feasibly be obtained in
the main trial, and thereby inform a decision as to whether
or not to undertake the main trial. However, the criterion
on which such a decision should be taken is unclear. A
straightforward approach is simply to produce a point es-
timate from the pilot study and compare this with the
MID or other predetermined cut-off, such that if the point
estimate is at least as large as the MID the main studycould proceed. For example, Ruzicka et al. [21] have pro-
posed for their pilot study that if at least 15% of partici-
pants exhibit a positive response to the intervention
tested, a full trial would be warranted. However, at their
intended sample size of 40, a 95% confidence interval (CI)
around a point estimate of 15% would extend from ap-
proximately 7 to 29% (using the Wilson method), indicat-
ing a very imprecise estimate on which to base a decision
regarding progression to a main trial.
Westlund and Stuart [22] have shown through simula-
tions that this imprecision also leads to inappropriate de-
cisions to proceed or not to proceed to a main trial, if the
point estimate from the pilot study either overestimates or
underestimates, respectively, the MID. Table 1 shows the
percentages of simulated pilot studies in which a decision
to proceed to a main trial would be taken on the criterion
of the point estimate exceeding the MID (assumed to be a
standardized effect of 0.25). For studies estimating a true
effect lower than the MID, a mistaken decision to proceed
to a main trial would be taken in 19% and 43% of studies
for true standardized effects of 0.00 and 0.20, respectively.
Conversely, mistaken decisions not to proceed would be
taken in 19% and 3% of studies for true standardized ef-
fects of 0.50 and 0.80, respectively.
Using a confidence interval around a between-group effect
to decide whether to proceed to main trial
Another possibility is to construct a CI for the between-
group effect—here, a mean difference will be assumed—
and observe where the MID lies in relation to this CI [23].
If the lower bound of the CI lies above the MID, all plaus-
ible values of the true treatment effect would be at least as
large as the MID. One can therefore be reassured, at the
appropriate level of confidence, that at an effect of at least
the MID will be observed in the main trial (the same inter-
pretation could be made if the lower bound happened to
lie precisely on the MID). However, as noted earlier, the
likely small size of the pilot study would produce a wide
CI, making it hard to exclude the MID from the CI, and
thus with little probability that the main trial would be im-
plemented. Moreover, a judgement on a CI in terms of
the inclusion or exclusion of a particular value is equiva-
lent to a hypothesis test (at a 5% significance level for a
95% CI), which could thereby prejudge the conclusion of
the main trial. For example, if the CI included the null
value of the treatment effect this would serve to reject the
alternative hypothesis that would be tested in the main
trial—but misleadingly, given that the chance of a type 2
error (false negative) would be unacceptably high in a typ-
ical pilot study.
An alternative, less stringent criterion, described by
Arnold et al. [24], would be satisfied if the MID lies
within (rather than necessarily below) the CI, suggesting
that the MID is among the plausible values of the effect
Table 1 Percentage of simulated pilot studies, estimating differing true standardized effect sizes, in which a main trial would be
favoured when the observed point estimate exceeded the minimum important difference (0.25). One hundred thousand simulations
were performed for each scenario [22]
True standardized effect size
Below MID Above MID
0.00 0.20 0.50 0.80
Pilot studies (%) indicating progression to main trial 19 43 81 97
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add the requirement that the point estimate of the treat-
ment effect should be greater than zero (or, equivalently,
below zero if a negative effect is of interest). However, in
this approach, unless the MID lies at or very close to the
lower bound of the CI, a range of other values, smaller
than the MID, would also be plausible estimates of the
effect to be observed in the main trial. Furthermore, if
the point estimate was smaller than the MID, this
method could have the inappropriate consequence that
the smaller the pilot study—and hence the wider the
CI—the more likely it is that the MID would be cap-
tured by the upper bound of the CI, and a decision to
undertake the main trial thereby endorsed.
This method of assessing the MID was used in a pilot
study (n = 12) of splinting for spasticity in stroke survivors
[25]. The assumed MID, expressed as a between-group
difference in percentage improvement, was 40% for each
outcome. On the basis of four outcomes for which a 95%
CI included this MID, progression to a main trial was con-
sidered to be warranted. As Fig. 1 demonstrates, however,
the wide CIs show the imprecision of these estimates, and
in the case of three of the outcomes (A, B and C), they in-
dicate the very wide range of alternative values below the
MID also included within the CI.
Both when requiring the MID to lie below the CI and
when requiring it to lie within it, the width of the CI for a
continuous outcome, and hence the decision made re-
garding the MID, will depend upon the standard deviation
of the treatment effect. In a small pilot study, this will be
estimated imprecisely. Lack of precision is thus problem-
atic for any formal decisions made regarding a main trial.
Simulated example
Figure 2 shows confidence intervals calculated on simu-
lated data for 20 pilot studies—of a typical size of n = 34
[12]—each estimating a mean difference of 10 for the
unknown true treatment effect, with a standard devi-
ation of 20. The MID is assumed to be 4. If progression
to a main study were determined on the basis of the lower
bound of the CI lying above the MID, this decision would
be negative in 9 (4, 7, 8, 9, 13, 14, 16, 18, 19) of the simu-
lated pilot studies and affirmative in the other 11. As only
one pilot study would actually be performed, this illus-
trates how the decision regarding progression to the maintrial would be very much at the mercy of sampling vari-
ability. It can also be noted that if the criterion were
switched to that of including a value of at least the MID
within the CI, all of the studies would favour the main
trial. However, in six of the studies (7, 8, 13, 14, 16), a wide
range of effects lower than the MID would be plausible al-
ternative estimates of the true treatment effect. Which of
the two interpretations of the CI is chosen clearly has a
marked effect on the likelihood of recommending the
main trial. Furthermore, in two of the studies (12 and 19),
where the lower bound of the CI lies extremely close to the
MID, if the criterion were that of requiring the MID to lie
below the CI a once-and-for-all decision on a main trial
would be made on the basis of a very small margin. Small
arbitrary changes in the sample size of these two studies
(two fewer participants in study 12 or two additional partic-
ipants in study 19) would reverse the decision.
Thus, in a typically small pilot study, generating a wide
CI, if a judgement is made on the basis of the MID lying
within the CI, a decision to proceed to the main trial
might be made too readily because values smaller than the
MID are also likely to be included in the CI, and would
therefore be plausible alternative values of the treatment
effect to be found in the main trial. Conversely, when the
MID is required to lie below the CI, a decision either to
proceed or not to proceed with the main trial might be
made too readily owing to random sampling variability af-
fecting the lower bound of the CI. In both cases, a defini-
tive decision would be made on proceeding to a main
trial—which would, if conducted, gather robust evi-
dence—on the comparatively scant evidence produced by
a pilot study.
It has been suggested that a range of confidence levels,
including and extending below 95%, could be used to
evaluate treatment effects from a pilot study [23]; the
largest confidence level at which the MID is excluded
from the CI represents the degree to which the re-
searcher is reassured of attaining the MID in the main
trial. This method is shown in Fig. 3 for study 18 in the
simulation. The highest confidence level at which the
MID is excluded from the CI is 75%, and it is therefore
with a corresponding degree of reassurance that progres-
sion to the main trial could be recommended. Whilst
the focus on varying levels of confidence allows a more
considered and less automatic decision on progression
Fig. 1 Estimated treatment effects, with 95% confidence intervals, reported for four outcomes by Sheehan et al. [25]. A difference in percentage
improvement of 40% (indicated by the dashed horizontal reference line) was taken to be the minimum important difference
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method is still vulnerable to sampling imprecision.
A further difficulty, common to each of the above
strategies, is that unless an external pilot study is run in
exactly the same way as the proposed main trial—in the
same clinical population, in comparable centres, with
equivalent strategies to prevent bias or confounding,
with a similar level of compliance with the study proto-
col, and with the same covariates in the analysis—the es-
timate from the pilot study may be systematically biased,Fig. 2 Simulated data for 20 pilot studies (each n = 34) estimating an unkn
with an assumed minimum important difference of 4 (dashed horizontal re
observed underlying standard deviations range from 12.6 to 24.8and thereby an unreliable indicator of what might occur
in the main trial. Biased estimates may also arise in a
small pilot study through substantial random baseline
imbalance (referred to as ‘chance bias’ [26]). For ex-
ample, in a randomized pilot study of treatments for
Achilles tendon pain (n = 8 in each of two groups),
Chester et al. [27] noted marked baseline differences be-
tween groups in sex (4 males versus 7 males), additional
pathologies (6 versus 2) and mean duration of symptoms
(23 months versus 14 months).own ‘true’ treatment effect of 10, with a standard deviation of 20, and
ference line). Error bars are 95% confidence intervals, and the
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between-group effects if these are used both to decide on
progression to a main trial and to determine its sample
size [19, 22]. In the first case, a decision to proceed to the
main trial is only likely to be made if the estimate from
the pilot study appears to be greater than or equal to the
MID; estimates below the MID are clearly very unlikely to
support progression to a main trial. Thus, trials that are
recommended on this basis are liable to be associated with
pilot studies that have overestimated the true MID. As
sample size calculations would likely only be performed
when the observed treatment effect favoured a main trial
in this way, these calculations are in turn liable to be based
on overestimates of the true MID, resulting in a main
study that would be underpowered [19, 22].
Within-group estimates of treatment effect
Sometimes, a pilot or feasibility study might analyse
within-group effects as a basis for recommending a future
trial. For example, Garcia et al. [28] and Galantino et al.
[29] derived such estimates from single-group feasibility
studies of acupuncture for cancer pain (n = 51), and tai
chi for breast cancer (n = 12), respectively. One reason
why a trialist might wish to use a pilot or feasibility study
in this way is to seek reassurance that a new untested
intervention is effective in its own right, before proceeding
to compare it with standard therapy or placebo (though,
importantly, a single-group analysis such as this would
not permit a robust causal inference as to the effect of the
intervention on the outcome).
In such an approach, a CI might be constructed around a
within-group estimate of effect for the new intervention, in
relation to a minimum clinically important effect—in thisFig. 3 Confidence intervals for the estimated treatment effect in study 18 (
to 70%. The dashed horizontal reference line indicates the minimum impocase, a minimum important change (MIC)—and inter-
preted in a similar way to a between-group effect (though
in the two examples given [28, 29], no CIs were presented
and no MICs were cited). This approach would not encour-
age an inappropriate judgement as to the conclusion of the
main trial, in the way that estimating a between-group ef-
fect might, as it is answering a different question—one of
absolute rather than relative effectiveness. However, it faces
the same difficulties in terms of how to interpret the rela-
tionship between the MIC and the CI, and is subject to
similar problems of sampling imprecision.
Conclusion
On the basis that it is normally unwise simply to ignore
information, trialists may wish to calculate and examine
estimates of treatment effect from pilot or feasibility
studies, to gain some informal reassurance (or not) of
what might be expected in the main trial. However, if
the size of the pilot or feasibility study has not been for-
mally calculated to provide an appropriate level of preci-
sion, these estimates are based on relatively meagre
evidence and are therefore unreliable, and may result in
inappropriate decisions either to proceed or not to
proceed to a main trial. Moreover, it is not clear how
they should most appropriately be interpreted. Such esti-
mates should not therefore play a part in any formal
decision-making regarding progression to a main trial,
unless perhaps combined with other prior robust infor-
mation, such as in a Bayesian decision model [23, 30].
Moreover, treatment effects calculated from pilot studies
should not be among the parameter estimates used in
sample size calculations for a main trial, as the targeted
treatment effect is predominantly a matter of judgement,n = 34) in the simulated example, at varying confidence levels from 95
rtant difference
Sim Pilot and Feasibility Studies           (2019) 5:107 Page 6 of 7not statistics; the effect one might detect does not deter-
mine the effect one needs to detect. Estimates of treat-
ment effect derived from pilot and feasibility studies
therefore provide information of very limited value and
may do more to mislead than to enlighten.
It might be argued that the imprecision that results from
small samples also affects other parameters that might be
estimated in a pilot or feasibility study, such as a standard
deviation. This is true, but not all such estimates are the
basis of a largely irrevocable decision such as whether or
not to proceed to a definitive study. A sample size based
on an estimated standard deviation can often be revised in
the light of further estimates from accruing data [31], and
as the specific concern is a possible underestimation of
the standard deviation, this can be at least partially offset
by applying an inflation factor to the estimate [5].
Finally, it should be noted that although the focus has
been on external pilot studies, key issues such as the impre-
cision of estimates of treatment effect, and the difficulties in
assessing them in relation to decisions on progression or
continuation to the main trial, are also relevant to internal
pilot studies.
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